Mastocytosis is a rare disease characterized by an abnormal increase of mast cells in tissues. We report a case of acute myeloid leukemia (AML) with t(8;21) and mast cell leukemia (MCL) in which the mastocytosis persisted after standard chemotherapy and allogeneic stem cell transplantation, although the myeloid leukemia achieved molecular complete remission soon after induction chemotherapy. Donor-type mast cells were noted on d31 after transplant. No c-kit mutation was found before or after the transplant. This represents the first reported case in which rapid engraftment of mast cells of donor origin was documented. Thus, the possibility that the mast cell originates from a common myeloid precursor cell may be questioned and a reactive process should be considered in some cases of systemic mastocytosis.
tor; stem cell transplantation Systemic mast cell disease is a disorder characterized by proliferation of mast cells in various tissues. Recently, the WHO proposed diagnostic criteria and a classification of systemic mastocytosis (SM). SM is divided into four categories: indolent SM, SM with an associated clonal hematologic nonmast cell lineage disease (AHNMD), aggressive SM, and mast cell leukemia (MCL). 1 MCL is a high-grade (malignant) mast cell disease with circulating MC and a very unfavorable prognosis. Differentiation of human MCs can be induced in vitro from c-kit+, CD34+ colony-forming cells and stem cell factor (SCF).
2 Two c-kit mutations (Val560Gly and Asp816Val) located in the tyrosine kinase domain have been reported in the human MCL cell line HMC-1. 3 One of them, Asp816Val, has been found more recently in patients with mastocytosis 4,5 and causes constitutional phosphorylation and ligand-independent activation of c-kit. 3, 6 We recently observed a case of acute myeloid leukemia (AML) with MCL for which the patient received allogeneic stem cell transplantation (SCT) for persistent mastocytosis. Interestingly, the mast cells derived from the donor stem cells only 31 days after transplant.
Materials and methods

Sequence analysis of the c-kit kinase domain
Bone marrow (BM) was obtained after informed consent was given. BM mononuclear cells (MNC) were isolated by Ficoll density gradient centrifugation. MNC were used for AML-ETO 7 and c-kit mutation analysis. Isolation of total RNA, cDNA synthesis, PCR amplification and direct nucleotide sequence analysis of the c-kit kinase domain extending from codon 510 to codon 626 and from codon 763 to 858 was performed as described. 8 
Chimeric study
Engraftment and monitoring the efficacy of SCT was assessed by detecting the chimeric status of BM MNC in the recipient with the use of short tandem repeat (STR) microsatellite marker on d31 and d95. Total BM cells were used for the chimeric study on d340. One STR marker (D6S442) was used, which had a high capacity between to discriminate recipient and donor. Their STRs were detected by polymerase chain reaction and were analyzed by using ABI310 Genetic Analyzer (Applied Biosystem, Foster City, CA, USA) and GeneScan software.
Case report
An 18-year-old man presented in July 2001 with fever and hepatosplenomegaly. His white blood cell count (WBC) was 32.6 Â 10 9 /l. The differential count showed 71% myeloblasts 8% segmented neutrophils, 1% eosinophils, 12% lymphocytes, and 8% mast cells. The BM smear revealed 37.5% myeloblasts and dense mast cell infiltration (40% of all nucleated cells). Some mast cells showed bi-or multi-lobulated nuclei ( Figure 1a ). There were no mediatorrelated symptoms or skin lesions present. The mast cells stained positive for CD117, tryptase, chloroacetate-esterase and toluidine blue. A diagnosis of AML-M2 was estab-lished according to FAB criteria. Cytogenetic studies showed t(8;21) (q22;q22). Induction chemotherapy (idarubicin, 12 mg/m 2 /day, days 1-3; cytarabine, 100 mg/m 2 / day, days 1-7) ('3+7 protocol') was administered. The patient entered complete remission with disappearance of peripheral mast cells, but BM mastocytosis (27.5%) persisted. He received one course of consolidation chemotherapy in August. Since persistent mastocytosis and hepatosplenomegaly, he received allogeneic peripheral blood SCT from his brother in December 2001. The conditioning regimen consisted of 16 mg/kg busulfan and 120 mg/kg cyclophosphamide. Methotrexate and cyclosporin-A were administered as graft-versus-host disease (GVHD) prophylaxis. His absolute neutrophil count was 0.5 Â 10 9 /l on d14 and platelet count over 20 Â 10 9 /l on d20. On d31 after PBSCT, he showed complete hematopoietic recovery. We performed BM studies and still found a dense mast cell infiltration (40%) with some spindle-shaped mast cells (Figure 1b) .
We analyzed the transcript of AML-ETO at diagnosis, after induction chemotherapy, and after SCT. The AML-ETO transcript could be seen on diagnosis; it disappeared after induction chemotherapy. The analysis proved that the patient entered molecular remission after induction. A c-kit mutation analysis found there was no Asp820Gly mutation. No other c-kit mutation could be found in codon 510-626 and codon 763-858, before or after SCT. Chimerism studies were performed on d31, d95 and d340, and a total donor genotype was first noted after d31 (Figure 2 ). This proved indirectly that the mast cells after SCT were derived from donor hematopoietic stem cells. Now the patient is 370 days after transplantation and still has pancytopenia and hepatosplenomegaly. No GVHD was observed during the course.
Discussion
A number of studies have suggested an association between BM mastocytosis and myelodysplastic or myeloproliferative syndromes. Some suggest that the two cell types come from a common myeloid precursor, then transform to leukemic blast or mast cells. In our patient, the initial diagnosis was AML with t(8;21) associated with BM and peripheral mastocytosis. Interestingly, BM mastocytosis persisted through the entire clinical course, when molecular complete remission was achieved, and even when donor stem cells were the apparent source of MCs after SCT. The hypothesis of a reactive MC process would be in line with the observation that the MC genotype switched from recipient to donor. Donor-type mastocytosis after SCT had been reported by Fodinger et al. 9 They proved MCs derived in vivo from the earliest BM hematopoietic progenitor cells. In their case, the enriched MCs were the recipient genotype 3 months after BM transplantation, but showed the donor genotype 6 months after transplant. In our patient, the MCs displayed the donor genotype immediately after engraftment. Fodinger et al considered that recurrence of clonal disease of donor origin after BMT should be excluded by further genetic study and concluded that the development of human MCs in vivo from their precursor cells seem to be a prolonged process. Development and differentiation of human MCs in vitro (with SCF as growth factor) takes about 4-10 weeks. 2, 10, 11 In our patient, however, the time for differentiation (only 31 days) was shorter than theirs and comparable to the in vitro studies. Owing to the short interval, a reactive process was more favored. The only difference between their patient and ours 
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is the origin of hematopoietic stem cells used for transplantation. We used peripheral hematopoietic stem cells, in contrast to BM stem cells. Interestingly, we found no c-kit mutation among codon 510-626 and codon 763-858. There must be an unknown mechanism in the BM microenvironment which induced mastocytosis, and this mechanism was refractory to chemotherapy, and even allogeneic SCT.
Since BM mononuclear cells were used for the chimeric studies on d31 and d95, mast cells may not be in the mononuclear fraction. We therefore used unfractionated BM cells for the chimeric study on d340, and full donor type could still be seen. This proved, although indirectly, that the mast cells were derived from the donor on d340.
Inbred mutant mice represent useful tools for studying mast cell biology in transplantation experiments. There are two strains of mice with MC deficiency. In W/W v mice, both the anemia and the MC deficiency can be cured by infusion of bone marrow from a wild-type donor, whereas this is not the case in Sl/Sl d mice. 12 From these experiments, it was suggested that the mast cell deficiency in the W/W v mice might be because of an intrinsic abnormality of BMderived MC precursors. This condition is now known as ckit deficiency. The MC deficiency in the Sl/Sl d mice was presumed to be the result of an abnormality in the microenvironment required for MC differentiation. This has now been determined to be a deficiency of SCF, which is the ligand for c-kit. There is another MC-deficient mouse strain with homozygous mutations at the microphthalmia (mi) gene. 13 In these mice, the MCs are unresponsive to proliferative stimuli because of defects in the regulation of c-kit expression.
14 Since our patient had no known c-kit mutation and donor origin MCs after SCT, the cause of mastocytosis may be not because of constitutional activation of c-kit. Uncontrollable production of SCF from the microenvironment may be the cause of the mastocytosis in our patient.
Despite significant advances in research on mastocytosis, curative treatment is not yet available. Treatment of patients who have SM with AHNMD entails individualized management of MC-mediated symptoms and signs relevant to specific organ systems as in indolent patients. Chemotherapy has often been seen to have a greater effect on the associated hematologic disease, and little or no effect on mast cell disease. Hematopoietic SCT does not seem to offer more hope as a treatment strategy in mastocytosis. We reviewed the peer-reviewed published literature and found only three SM patients with AHNMD who had undergone allogeneic SCT. 9, 15, 16 In two of the cases, although the associated hematologic disorder seemed to have resolved, mastocytosis persisted. Only one patient entered remission with disappearance of all the BM MCs after allogeneic SCT, for more than 24 months. Except in one case mentioned previously, the origin of MC after SCT was not disclosed. Our case is the first reported case in which the donor origin of MCs was documented immediately after engraftment.
Our observations suggest that not all cases of SM are clonal and some may be reactive, especially in cases without a c-kit clonal mutation. Further investigations may provide additional insight in to the molecular basis of this heterogeneous disease and allow guidance concerning prognosis and targeted therapies.
